Safety and immunogenicity of a mosquito saliva peptide-based vaccine: a randomised, placebo-controlled, double-blind, phase 1 trial

Manning, Jessica E.; Oliveira, Fabiano; Coutinho-Abreu, Iliano V.; Herbert, Samantha; Meneses, Claudio; Kamhawi, Shaden; Baus, Holly Ann; Han, Alison; Czajkowski, Lindsay; Rosas, Luz Angela; Cervantes-Medina, Adriana; Athota, Rani; Reed, Susan; Mateja, Allyson; Hunsberger, Sally; James, Emma L.; Pleguezuelos, Olga; Stoloff, Gregory; Valenzuela, Jesús G.; Memoli, Matthew J.

doi:10.1016/s0140-6736(20)31048-5

Cited by 46 publications

(32 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, in the context of malaria, mice immunized with antiserum against an Anopheles gambiae salivary protein (TRIO) showed partial protection against plasmodium infection (Dragovic et al, 2018 ). In humans, the results from the first safety and immunogenicity phase 1 clinical trial for an universal mosquito-borne disease vaccine (AGS-v) have recently been published (Manning et al, 2020 ). The vaccine is composed of four salivary peptides from A. gambiae salivary glands that are common in many other mosquito vectors.…”

Section: Vaccine Prospectmentioning

confidence: 99%

Aedes Mosquito Salivary Components and Their Effect on the Immune Response to Arboviruses

Guerrero

Cantaert

Missé

2020

Front. Cell. Infect. Microbiol.

View full text Add to dashboard Cite

Vector-borne diseases are responsible for over a billion infections each year and nearly one million deaths. Mosquito-borne dengue virus, West Nile, Japanese encephalitis, Zika, Chikungunya, and Rift Valley Fever viruses constitute major public health problems in regions with high densities of arthropod vectors. During the initial step of the transmission cycle, vector, host, and virus converge at the bite site, where local immune cells interact with the vector's saliva. Hematophagous mosquito saliva is a mixture of bioactive components known to modulate vertebrate hemostasis, immunity, and inflammation during the insect's feeding process. The capacity of mosquito saliva to modulate the host immune response has been well-studied over the last few decades and has led to the consensus that the presence of saliva is linked to the enhancement of virus transmission, host susceptibility, disease progression, viremia levels, and mortality. We review some of the major aspects of the interactions between mosquito saliva and the host immune response that may be useful for future studies on the control of arboviruses.

show abstract

Section: Vaccine Prospectmentioning

confidence: 99%

Aedes Mosquito Salivary Components and Their Effect on the Immune Response to Arboviruses

Guerrero

Cantaert

Missé

2020

Front. Cell. Infect. Microbiol.

View full text Add to dashboard Cite

show abstract

“…[34][35][36] Recently, a vaccine against mosquito saliva targeting the transmission of multiple mosquito-borne pathogens was investigated and found to be safe and immunogenic. 37…”

Section: Transmission Blocking Vaccinesmentioning

confidence: 99%

Towards Eradication of Malaria: Is the WHO’s RTS,S/AS01 Vaccination Effective Enough?

Arora

Anbalagan

Pannu

2021

RMHP

View full text Add to dashboard Cite

Background: Recent advances in mosquito eradication and antimalarial treatments have reduced the malaria burden only modestly. An effective malaria vaccine remains a high priority, but its development has several challenges. Among many potential candidates, the RTS,S/AS01 vaccine (Mosquirix TM) remains the leading candidate. Objective and Method: This review aims to understand the advances in the RTS,S/AS01 vaccine, and future comments regarding the vaccine's effectiveness in malaria eradication. Literature review for the past five decades was performed searching PubMed, EMBASE Ovid, and Cochrane Library, with using the following search items: ("malaria" OR "WHO's malaria" OR "Plasmodium falciparum" OR "RTS,S" OR "RTS,S/AS01" OR "RTS,S/AS02" OR "pre-erythrocytic malaria" OR "circumsporozoite" OR "Mosquirix") AND ("vaccine" OR "vaccination"). Results: RTS,S/AS01, a recombinant pre-erythrocytic vaccine containing Plasmodium falciparum surface-protein (circumsporozoite) antigen, is safe, well-tolerated, and immunogenic in children. Three doses, along with a booster, have a modest efficacy of about 36% in children (age 5-17 months) and about 26% in infants (age 6-12 weeks) against clinical malaria during a 48-month follow-up. However, the efficacy varies among population subgroups and with the parasite strain, it reduces without a booster and offers protection for a limited duration. Because of its potential cost-effectiveness and positive public health effect, the vaccine is being investigated in a pilot program for mortality benefits and broader deployment. Conclusion: The RTS,S/AS01 vaccine prevents malaria; however, it should be considered another addition to the malaria-control program and not as an eradication tool because of its relatively low to modest efficacy.

show abstract

“…Since these proteins can affect the innate and adaptive immune responses of the host, they are tremendously functional in our search for a vaccine [67]. A Phase 1 trial of the experimental vaccine AGS-V indicated that the vaccine is safe and induces a robust immune response in healthy volunteers [2]. The volunteers' blood tests showed that the vaccine, along with the adjuvant, produced a significant immune response to mosquito salivary peptides, supporting the need for further research to test the vaccine's efficacy against individual pathogens [2].…”

Section: Mosquitoes and O+ Blood Groupmentioning

confidence: 99%

“…A Phase 1 trial of the experimental vaccine AGS-V indicated that the vaccine is safe and induces a robust immune response in healthy volunteers [2]. The volunteers' blood tests showed that the vaccine, along with the adjuvant, produced a significant immune response to mosquito salivary peptides, supporting the need for further research to test the vaccine's efficacy against individual pathogens [2]. After using flow cytometry and multiplex cytokine bead array assays, both Th1 and Th2 human immune responses were detected, including delayed effects on cytokine levels in the blood, and immune cell compositions in the skin and bone marrow, for up to 7 days post-bites [1].…”

Section: Mosquitoes and O+ Blood Groupmentioning

confidence: 99%

“…As the salivary gland extract (SGE) of mosquitoes has shown to have immunomodulatory abilities [1] that are long-lasting, and previous efforts at adjuvanted-vaccinations (against arboviral infections ) have shown them to be safe [2]. Therefore, we would like to propose the use of mosquito SGE as part of an adjuvanted-SARS-CoV2-vaccine to all vulnerable populations who are of A, B, and AB blood groups.…”

Section: Mosquitoes and O+ Blood Groupmentioning

confidence: 99%

See 1 more Smart Citation

Mosquito saliva as a potential source for COVID-19 Preventive Medicine – A brief review

2020

SJVD

View full text Add to dashboard Cite

Safety and immunogenicity of a mosquito saliva peptide-based vaccine: a randomised, placebo-controlled, double-blind, phase 1 trial

Cited by 46 publications

References 31 publications

Aedes Mosquito Salivary Components and Their Effect on the Immune Response to Arboviruses

Aedes Mosquito Salivary Components and Their Effect on the Immune Response to Arboviruses

Towards Eradication of Malaria: Is the WHO’s RTS,S/AS01 Vaccination Effective Enough?

Mosquito saliva as a potential source for COVID-19 Preventive Medicine – A brief review

Contact Info

Product

Resources

About